120 related articles for article (PubMed ID: 19190239)
1. Potential treatment options after first-line chemotherapy for advanced NSCLC: maintenance treatment or early second-line?
Gridelli C; Maione P; Rossi A; Ferrara ML; Bareschino MA; Schettino C; Sacco PC; Ciardiello F
Oncologist; 2009 Feb; 14(2):137-47. PubMed ID: 19190239
[TBL] [Abstract][Full Text] [Related]
2. Sequential, alternating, and maintenance/consolidation chemotherapy in advanced non-small cell lung cancer: a review of the literature.
Grossi F; Aita M; Follador A; Defferrari C; Brianti A; Sinaccio G; Belvedere O
Oncologist; 2007 Apr; 12(4):451-64. PubMed ID: 17470688
[TBL] [Abstract][Full Text] [Related]
3. Update on the role of topotecan in the treatment of non-small cell lung cancer.
Stewart DJ
Oncologist; 2004; 9 Suppl 6():43-52. PubMed ID: 15616149
[TBL] [Abstract][Full Text] [Related]
4. Improving patient management in metastatic non-small cell lung cancer.
Vansteenkiste J
Lung Cancer; 2007 Aug; 57 Suppl 2():S12-7. PubMed ID: 17686440
[TBL] [Abstract][Full Text] [Related]
5. Is there a role for maintenance therapy in non-small-cell lung cancer? An emerging issue.
Petrelli F; Ghilardi M; Cremonesi M; Cabiddu M; Barni S
Expert Rev Anticancer Ther; 2009 Oct; 9(10):1455-65. PubMed ID: 19828007
[TBL] [Abstract][Full Text] [Related]
6. Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer.
Di Maio M; Chiodini P; Georgoulias V; Hatzidaki D; Takeda K; Wachters FM; Gebbia V; Smit EF; Morabito A; Gallo C; Perrone F; Gridelli C
J Clin Oncol; 2009 Apr; 27(11):1836-43. PubMed ID: 19273711
[TBL] [Abstract][Full Text] [Related]
7. The role of maintenance chemotherapy in advanced nonsmall cell lung cancer.
Jalal SI; Ademuyiwa FO; Hanna NH
Curr Opin Oncol; 2009 Mar; 21(2):110-5. PubMed ID: 19532011
[TBL] [Abstract][Full Text] [Related]
8. The role of maintenance treatment in advanced non-small-cell lung cancer: reality or early second line?
Gridelli C; Rossi A; Maione P; Ambrosio R; Barbato V; Bareschino MA; Schettino C; Palazzolo G; Sacco PC
Clin Lung Cancer; 2010 Nov; 11(6):374-82. PubMed ID: 21062728
[TBL] [Abstract][Full Text] [Related]
9. Maintenance treatment of advanced non-small-cell lung cancer: results of an international expert panel meeting of the Italian association of thoracic oncology.
Gridelli C; de Marinis F; Di Maio M; Ardizzoni A; Belani CP; Cappuzzo F; Ciardiello F; Fidias P; Paz-Ares L; Perrone F; Pirker R; De Petris L; Stahel R
Lung Cancer; 2012 Jun; 76(3):269-79. PubMed ID: 22266040
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic strategy for treatment of metastatic non-small cell lung cancer.
Berhoune M; Banu E; Scotte F; Prognon P; Oudard S; Bonan B
Ann Pharmacother; 2008 Nov; 42(11):1640-52. PubMed ID: 18957625
[TBL] [Abstract][Full Text] [Related]
11. Treatment of non-small cell lung cancer patients with performance status2 (PS2).
Boukovinas I; Kosmidis P
Lung Cancer; 2009 Jan; 63(1):10-5. PubMed ID: 18586349
[TBL] [Abstract][Full Text] [Related]
12. Identifying an optimum treatment strategy for patients with advanced non-small cell lung cancer.
Grossi F; Gridelli C; Aita M; De Marinis F
Crit Rev Oncol Hematol; 2008 Jul; 67(1):16-26. PubMed ID: 18243728
[TBL] [Abstract][Full Text] [Related]
13. Do the time to chemotherapy response and the dose intensity have an impact on patient outcome in advanced non-small cell lung cancer?
Radosavljevic D; Golubicic I; Gavrilovic D; Kezic I; Jelic S
J BUON; 2009; 14(2):203-9. PubMed ID: 19650167
[TBL] [Abstract][Full Text] [Related]
14. [Second-line treatment and targeted therapy of advanced lung cancer].
Nakamura Y; Yamamoto N
Gan To Kagaku Ryoho; 2009 May; 36(5):710-6. PubMed ID: 19461168
[TBL] [Abstract][Full Text] [Related]
15. The 800-lb gorilla we all ignore: treatment of NSCLC in elderly and PS 2 patients.
Devlin JG; Langer CJ
Clin Adv Hematol Oncol; 2007 Mar; 5(3):216-33. PubMed ID: 17519883
[TBL] [Abstract][Full Text] [Related]
16. Survival among patients with platinum resistant, locally advanced non-small cell lung cancer treated with platinum-based systemic therapy.
d'Amato TA; Pettiford BL; Schuchert MJ; Parker R; Ricketts WA; Luketich JD; Landreneau RJ
Ann Surg Oncol; 2009 Oct; 16(10):2848-55. PubMed ID: 19609620
[TBL] [Abstract][Full Text] [Related]
17. Pemetrexed for the treatment of non-small-cell lung cancer.
Manegold C; Schmid-Bindert G; Pilz LR
Expert Rev Anticancer Ther; 2009 Sep; 9(9):1195-209. PubMed ID: 19761423
[TBL] [Abstract][Full Text] [Related]
18. Pemetrexed in first-line treatment of non-small cell lung cancer.
Esteban E; Casillas M; Cassinello A
Cancer Treat Rev; 2009 Jun; 35(4):364-73. PubMed ID: 19269106
[TBL] [Abstract][Full Text] [Related]
19. Management of unfit older patients with advanced NSCLC.
Gridelli C; Maione P; Rossi A; Palazzolo G; Colantuoni G; Rossi E
Cancer Treat Rev; 2009 Oct; 35(6):517-21. PubMed ID: 19457617
[TBL] [Abstract][Full Text] [Related]
20. Is there a role for consolidative stereotactic body radiation therapy following first-line systemic therapy for metastatic lung cancer? A patterns-of-failure analysis.
Rusthoven KE; Hammerman SF; Kavanagh BD; Birtwhistle MJ; Stares M; Camidge DR
Acta Oncol; 2009; 48(4):578-83. PubMed ID: 19373699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
